Literature DB >> 1616868

Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening.

G Castiglione1, G Grazzini, S Ciatto.   

Abstract

Seven hundred and eighty-six subjects spontaneously referring to our Center performed two guaiac (Rehydrated Hemoccult II (R.HO), and Hemoccult Sensa (HO S.)), and two immunochemical (OC Hemodia (Hdia) and Hemeselect (Hsel)) faecal occult blood tests on three consecutive faecal determinations. The positivity rates of 3 day R.HO, HO S., Hdia, and Hsel were 4.8%, 5.6%, 8.4% and 11.2% respectively. One hundred and thirty-five of the 150 subjects with at least one positive test completed the diagnostic work-up. Cancer was detected in three subjects and adenomas in 15. Three-day specificity estimates of R.HO, HO S., Hdia and Hsel in the overall series were 96.1%, 96.0%, 93.8% and 91.2% respectively, the differences between guaiac and immunochemical tests being significant. Corresponding values of specificity as determined on the first faecal sample only in the overall series were 98.1%, 98.3%, 96.1% and 94.9% respectively. No significant difference in specificity is evident when 3-day guaiac tests are compared to 1-day immunochemical ones. Three-day immunochemical testing is not recommended for screening purposes due to its very low specificity. Nevertheless, 1-day immunochemical testing is almost as specific as 3-day guaiac testing. A preliminary estimate of colonic neoplasms detection rates shows no difference as well. The benefit of 1-day testing on screening acceptability is evident, but the impact on sensitivity should be evaluated in a screening situation with a proper study design and a larger sample size.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616868      PMCID: PMC1977762          DOI: 10.1038/bjc.1992.197

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  5 in total

1.  Sensitivity of Hemoccult test for large bowel cancer in high-risk subjects.

Authors:  L Bertario; P Spinelli; L Gennari; P Sala; P Pizzetti; A Severini; G Cozzi; M Bellomi; F Berrino
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

2.  Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects.

Authors:  J D Hardcastle; W M Thomas; J Chamberlain; G Pye; J Sheffield; P D James; T W Balfour; S S Amar; N C Armitage; S M Moss
Journal:  Lancet       Date:  1989-05-27       Impact factor: 79.321

3.  Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects.

Authors:  J Kewenter; S Björk; E Haglind; L Smith; J Svanvik; C Ahrén
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

4.  Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark.

Authors:  O Kronborg; C Fenger; J Olsen; K Bech; O Søndergaard
Journal:  Scand J Gastroenterol       Date:  1989-06       Impact factor: 2.423

5.  Hemoccult sensitivity estimate in a screening program for colorectal cancer in the Province of Florence.

Authors:  G Castiglione; G Grazzini; A Poli; R Bonardi; S Ciatto
Journal:  Tumori       Date:  1991-06-30
  5 in total
  2 in total

1.  Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening.

Authors:  Adolfo Parra-Blanco; Antonio Z Gimeno-García; Enrique Quintero; David Nicolás; Santiago G Moreno; Alejandro Jiménez; Manuel Hernández-Guerra; Marta Carrillo-Palau; Yoshinobu Eishi; Julio López-Bastida
Journal:  J Gastroenterol       Date:  2010-02-17       Impact factor: 7.527

2.  Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination.

Authors:  M J Solomon; R S McLeod
Journal:  CMAJ       Date:  1994-06-15       Impact factor: 8.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.